Moreover, tumours that contain anaplastic lymphoma kinase (ALK) fusion oncogene rearrangements, usually associated with never smokers, a younger age group and adenocarcinoma with signet or acinar histology, are sensitive to ALK-targeted therapies [3]. The gene discussed is ALK; the disease is adenocarcinoma.